In validation cohort 3, which was applied to test whether the ctDNA PTPRD mutations’ prediction efficiency was consistent with tissue PTPRD mutations, there was a tendency that median PFS of the ctDNA PTPRD mutations was longer than that of the WT group in NSCLC, despite not statistically significant (6.36 vs 2.36 months, HR=0.71, p=0.0603, Fig. 3a). The gene discussed is PTPRD; the disease is non-small cell lung carcinoma.